Lutris Pharma
Anticancer Therapy for Patients Treated with EGFR Inhibitors
Company Overview
Snapshot
Founded in December 2015, Lutris Pharma operates with 1–10 employees. The company has raised $40.69M across four funding rounds from six investors. In January 2025, Lutris Pharma secured funding from Columbus Venture Partners, marking a significant milestone in its development.
Business overview
Lutris Pharma is a clinical-stage biopharmaceutical company focused on improving anticancer therapies by reducing cutaneous side effects associated with epidermal growth factor receptor (EGFR) inhibitors. The company's core product is LUT014, a proprietary topical B-Raf inhibitor designed to mitigate dermal toxicities like acneiform lesions, thereby allowing patients to continue EGFR inhibitor treatment without interruption. Lutris Pharma serves the oncology and dermatology markets, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In October 2024, Lutris Pharma completed enrollment in its Phase 2 trial for LUT014, targeting EGFR inhibitor-induced acneiform rash in metastatic colorectal cancer patients. This milestone indicates significant progress in the clinical development of its lead candidate, signaling to investors a clear advancement towards potential market entry and addressing a critical unmet need in cancer supportive care.
Company Intelligence Q&A
- What is Lutris Pharma's primary focus?
- Lutris Pharma is dedicated to developing therapies that improve the effectiveness of anticancer treatments and enhance the quality of life for patients undergoing EGFR inhibitor therapy by reducing associated cutaneous side effects.
- When did Lutris Pharma last raise funding?
- In January 2025, Lutris Pharma raised funding from investors including.
- What is LUT014?
- LUT014 is Lutris Pharma's proprietary topical B-Raf inhibitor, designed to decrease dermal toxicities and reduce acneiform lesions caused by EGFR inhibitors in cancer patients.
- Has Lutris Pharma received any grants?
- In October 2022, Lutris Pharma's founder and chairman received a grant from the California Institute of Regenerative Medicine (CIRM) to develop LUT017 for wound healing.
- What was a recent clinical development for LUT014?
- In October 2024, Lutris Pharma completed enrollment in its Phase 2 trial for LUT014, evaluating its efficacy in treating EGFR inhibitor-induced acneiform rash in patients with metastatic colorectal cancer.